

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Havey Adam</u>  (Last) (First) (Middle) 400 PROFESSIONAL DR, SUITE 400  (Street) GAITHERSBURG MD 20879  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [ EBS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Biodefense Division</u>
	3. Date of Earliest Transaction (Month/Day/Year) 06/15/2015	
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock <sup>(1)</sup>	06/15/2015		M		15,919	A	\$14.67	57,363	D	
Common Stock <sup>(1)(2)</sup>	06/15/2015		S		15,919	D	\$31.502 <sup>(3)</sup>	41,444	D	
Common Stock <sup>(4)</sup>	06/15/2015		M		9,773	A	\$15.83	51,217	D	
Common Stock <sup>(4)(2)</sup>	06/15/2015		S		9,773	D	\$31.665 <sup>(5)</sup>	41,444	D	
Common Stock <sup>(2)</sup>	06/15/2015		S		10,606	D	\$31.502 <sup>(6)</sup>	30,838	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option <sup>(1)</sup>	\$14.67	06/15/2015		M			15,919	(7)	03/11/2010	Common Stock	15,919	\$0	7,960	D	
Stock Option <sup>(4)</sup>	\$15.83	06/15/2015		M			9,773	(8)	03/12/2019	Common Stock	9,773	\$0	0	D	

**Explanation of Responses:**

- Consists of an option granted under the company's stock incentive plan on March 12, 2013.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.055 to \$31.77, inclusive.
- Consists of an option granted under the company's stock incentive plan on March 13, 2012.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.66 to \$31.72, inclusive.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.03 to \$31.76, inclusive.
- The option vested in three equal installments in March 2014, 2015 and 2016
- The option vested in three equal installments in March 2013, 2014 and 2015.

**Remarks:**

/s/ Eric Burt, attorney-in-fact      06/17/2015

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.